Exosomal miR-484 impairs CD8<sup>+</sup> T cell homeostasis in sepsis through the YPEL1/Cyclin E axis
Article Quality & Performance Metrics
Mint this article as an NFT
Not yet mintedCreate a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.
Abstract
Sepsis induces profound CD8+ T cell dysfunction, contributing to immunosuppression and poor outcomes. Exosomes mediate intercellular communication during sepsis, but the role of exosomal microRNAs in regulating CD8+ T cell homeostasis remains unclear. Sepsis patients and healthy controls are prospectively enrolled to investigate plasma exosomes and CD8+ T cell responses. Exosomes from sepsis patients (SE) promote CD8+ effector differentiation and dysregulate cell cycle progression compared to those from healthy donors (HE). miRNA sequencing identifies miR-484 as the most upregulated miRNA in SE. Functionally, SE-derived miR-484 suppresses YPEL1 expression in CD8+ T cells, leading to increased Cyclin E levels and aberrant cell cycle distribution. Inhibition of miR-484 restores YPEL1 and normalizes Cyclin E expression, which is associated with a reversal of the sepsis exosome-induced bias toward CD8+ effector differentiation. Our findings reveal that exosomal miR-484 impairs CD8+ T cell homeostasis in sepsis by targeting the YPEL1/Cyclin E pathway, highlighting a potential mechanism for immune dysregulation and a target for intervention.
| Reference Key |
openalex_W7163361551
Use this key to autocite in the manuscript while using
SciMatic Manuscript Manager or Thesis Manager
|
|---|---|
| Authors | Jiaqian Ling, Zhouyi Chen, Yile Zhou, Guangshan Jin, Yuanyang Chen, Jianxin Dong, Xia Sun, Yi Shi, Hao Fang |
| Journal | acta biochimica et biophysica sinica |
| Year | 2026 |
| DOI |
10.3724/abbs.2026107
|
| URL | |
| Keywords | Keywords not found |
Citations
No citations found. To add a citation, contact the admin at info@scimatic.org
Comments
No comments yet. Be the first to comment on this article.